Valuation: Black Diamond Therapeutics, Inc.

Market Cap 97.67M 87.82M 81.95M 74.27M 139M 9.29B 140M 983M 384M 4.82B 367M 359M 15.52B P/E 2026 *
-2.76x
P/E 2027 * -1.78x
Enterprise Value 97.67M 87.82M 81.95M 74.27M 139M 9.29B 140M 983M 384M 4.82B 367M 359M 15.52B EV / Sales 2026 *
15.6x
EV / Sales 2027 * -
Free-Float
99.34%
Yield 2026 *
-
Yield 2027 * -
1 day+1.19%
1 week-7.10%
Current month-9.81%
1 month-16.26%
3 months-8.60%
6 months-36.09%
Current year-30.04%
1 week 1.6
Extreme 1.6
1.86
1 month 1.6
Extreme 1.6
2.02
Current year 1.6
Extreme 1.6
3.97
1 year 1.6
Extreme 1.6
4.94
3 years 1.2
Extreme 1.195
7.66
5 years 1.18
Extreme 1.18
8.71
10 years 1.18
Extreme 1.18
46.25
Manager TitleAgeSince
Chief Executive Officer 62 2023-09-15
Chief Tech/Sci/R&D Officer 51 2021-08-10
Director of Finance/CFO 41 2024-10-06
Director TitleAgeSince
Director/Board Member 61 2017-02-28
Director/Board Member 47 2019-11-30
Director/Board Member 49 2018-11-30
Date Insider Type Main position Quantity % Market Cap. Importance
9/18/26 Free

Director

7,707 0.0134%
9/18/26 Free

Director

6,801 0.0118%
9/18/26
NEA Management Co. LLC
OtherCompany 0 0% -
Change 5-day change 1-year change 3-year change Capi.($)
+1.19%-7.10%-54.79%-25.76% 96.52M
-2.01%-7.86%+60.74%+70.97% 70.44B
+3.84%-11.02%+8.59%+57.43% 50.31B
+3.35%+1.42%+11.85%+40.01% 47.51B
+0.51%+1.51%+27.96%+31.43% 42.91B
+2.70%-3.66%+307.41%+547.01% 40.39B
+0.69%-3.44%+9.52%+96.59% 39.69B
+0.06%-2.02%+11.25%+43.27% 30.59B
+0.32%-7.76%+38.84%+1.84% 26.8B
-0.39%-6.92%-13.60%-14.40% 22.36B
Average +1.03%-5.26%+40.78%+84.84% 37.11B
Weighted average by Cap. +1.00%-4.90%+54.82%+102.70%

Financials

2026 *2027 *
Net sales 6.25M 5.62M 5.24M 4.75M 8.92M 595M 8.98M 62.93M 24.57M 309M 23.46M 22.96M 993M -
Net income -36.96M -33.23M -31.01M -28.11M -52.77M -3.52B -53.1M -372M -145M -1.83B -139M -136M -5.87B -64.65M -58.13M -54.24M -49.16M -92.3M -6.15B -92.87M -651M -254M -3.19B -243M -237M -10.27B
Net Debt - -
Projected Income Statement - Annual - Black Diamond Therapeutics, Inc.
Logo Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Employees
21
Date Price Change Volume
26-10-14 $1.700 +1.19% 1,069,363
26-10-13 $1.680 -5.08% 1,140,954
26-10-12 $1.770 -3.28% 377,692
26-10-09 $1.830 +1.10% 448,966
26-10-08 $1.810 -1.09% 784,998
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Black Diamond Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
1.700USD
Average target price
10.00USD
Spread / Average Target
+488.24%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Black Diamond Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. BDTX Stock